Clinica Chimica Acta最新文献

{"title":"Corrigendum to \"Irisin in thyroid diseases\" [Clin. Chim. Acta 564 (2025) 119929].","authors":"Qi Chen, Jing Wang, Kang Li, Jun-Qin Luan, Jing-Mei Li, Ya-Ting Wang","doi":"10.1016/j.cca.2024.120034","DOIUrl":"10.1016/j.cca.2024.120034","url":null,"abstract":"","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120034"},"PeriodicalIF":3.2,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steroid hormone concentrations in dried blood spots: A comparison between capillary and venous blood samples.","authors":"Anouk Olthof, Vera H de Kleijne, Anita Boelen, Annemieke C Heijboer","doi":"10.1016/j.cca.2024.120099","DOIUrl":"https://doi.org/10.1016/j.cca.2024.120099","url":null,"abstract":"<p><strong>Background: </strong>An important aspect of the shift towards dried blood spots (DBS) as a sample matrix for laboratory measurements, is the availability of robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods that can reliably quantify analyte concentrations in DBS. The development and validation of these LC-MS/MS methods, however, concerns an extensive process, for which large amounts of DBS samples are required. DBS are usually obtained from capillary blood samples, but they can also be prepared from venous (residual) blood samples, which are widely available in clinical laboratories. Therefore, we aimed to determine whether DBS prepared from (residual) venous blood samples, collected in EDTA blood tubes, can be used for future development and validation of LC-MS/MS methods to quantify steroid hormones in DBS.</p><p><strong>Methods: </strong>Capillary DBS and venous blood samples (EDTA tube and tube without additives) were collected from twenty healthy volunteers (12F/8M). From both venous blood samples, DBS were prepared volumetrically. Samples were analyzed using in-house developed LC-MS/MS methods for testosterone, androstenedione, 17-hydroxyprogesterone (17-OHP), cortisol, cortisone, corticosterone, and for dehydroepiandrosterone sulfate (DHEA-S).</p><p><strong>Results: </strong>DBS made from venous blood collected in EDTA tubes compared with capillary blood showed a correlation coefficient of ≥ 0.89 for all steroid hormones except corticosterone (0.67). DBS made from venous blood collected in tubes without additives showed a strong correlation with both DBS made from venous blood collected in EDTA tubes (≥0.97 for all steroid hormones) and capillary DBS (>0.90) except corticosterone (0.64).</p><p><strong>Conclusion: </strong>DBS prepared from (residual) venous blood collected in EDTA blood tubes can be used for future development and validation of LC-MS/MS methods to quantify steroid hormones, except for corticosterone, in capillary DBS.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120099"},"PeriodicalIF":3.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A nomogram model for predicting advanced liver fibrosis in patients with hepatitis B: A multicenter study.","authors":"Bo Hu, Li Yang, Rui-Bing Li, Jiao Gong, Er-Hei Dai, Wei Wang, Fa-Quan Lin, Chang-Min Wang, Xiao-Li Yang, Ying Han, Xiao-Long Qi, Jing Teng, Ya-Jie Wang, Cheng-Bin Wang","doi":"10.1016/j.cca.2024.120102","DOIUrl":"https://doi.org/10.1016/j.cca.2024.120102","url":null,"abstract":"<p><strong>Background: </strong>Biopsy is the gold standard method for diagnosing liver fibrosis. FibroScan is a non-invasive method of diagnosing liver fibrosis, but it still faces some limitations. This study aimed to establish a nomogram model and identify patients at high risk of advanced liver fibrosis associated with hepatitis B infection.</p><p><strong>Methods: </strong>Data were collected from 375 patients with hepatitis B who underwent liver biopsy. Patients were divided randomly into the training (n = 263) and validation sets (n = 112). Their demographic and clinical characteristics were analyzed using the least absolute shrinkage and selection operator regression (LASSO). A nomogram model was established to predict the fibrosis stage, and its performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA) and was compared with other recognized models.</p><p><strong>Results: </strong>In total, 209 patients with non-advanced fibrosis (S0-1) and 166 patients with advanced fibrosis (S ≥ 2) were included. Hyaluronic acid (HA), laminin, total cholesterol (TC), platelet, and age were entered into the nomogram model based on the LASSO analysis. The nomogram model for predicting advanced fibrosis exhibited a relatively high AUC in the training set. Compared with FIB4 and APRI, the nomogram model showed a better agreement between the actual status and predicted status based on the calibration curve. The nomogram model showed an AUC similar to FibroScan in the validation cohort, and showed high clinical net benefits in the training and validation sets.</p><p><strong>Conclusion: </strong>Our nomogram model can help identify patients with hepatitis B and advanced liver fibrosis.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120102"},"PeriodicalIF":3.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations for assessing commutability of a replacement batch of a secondary calibrator certified reference material.","authors":"Liesbet Deprez, Jesper V Johansen, Thomas Keller, Jeffrey Budd, Neil Greenberg, Cas Weykamp, Sverre Sandberg, Mauro Panteghini, Ferruccio Ceriotti, Elizabeth Barczak, Robert Rej, Pernille Kjeilen Fauskanger, Finlay MacKenzie, Johanna E Camara, Alicia N Lyle, W Greg Miller, Vincent Delatour","doi":"10.1016/j.cca.2024.120097","DOIUrl":"https://doi.org/10.1016/j.cca.2024.120097","url":null,"abstract":"<p><p>Commutable secondary certified reference materials (CRMs) play an essential role in the calibration hierarchy of many in-vitro diagnostic measurement procedures used in the medical laboratory. Therefore, sustainable availability of these CRMs is crucial to guarantee the long-term equivalence of results obtained for the clinical samples. The IFCC Working Group on Commutability in Metrological Traceability (WG-CMT) has published several recommendations for assessing the commutability of secondary calibrator CRMs. Performing a full commutability study according to these recommendations may present significant demands on the resources of CRM producers. This report provides recommendations for performing commutability equivalence assessments between existing CRMs of proven commutability and replacement batches of those CRMs. The approach evaluates the relationship of measurement results obtained with the relevant measurement procedures for the replacement batch versus the existing CRM batch. If this relationship is the same, the commutability properties of the replacement batch are considered equivalent to those of the existing CRM batch. Since the existing batch has a suitable commutability, the commutability of the replacement batch is also declared fit for purpose. Because this commutability equivalence assessment involves certain risks, a small number of representative clinical samples are included as safeguards. There are several prerequisites for performing the commutability equivalence assessment and producers of secondary CRMs will probably need to implement improvements before using this approach. However, once the improvements are implemented, the commutability equivalence assessment approach will significantly reduce the resources needed to maintain the supply of CRMs.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120097"},"PeriodicalIF":3.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric case of hemoglobin I-high Wycombe variant.","authors":"Ridwan B Ibrahim, Beverly Vispo, Titilope Fasipe, Sridevi Devaraj","doi":"10.1016/j.cca.2024.120098","DOIUrl":"https://doi.org/10.1016/j.cca.2024.120098","url":null,"abstract":"<p><p>Over 1400 variants of hemoglobin (Hb) have been identified and characterized with phenotypes ranging from clinically silent to severe clinical manifestations in carriers. Different analytical methods have been established to detect Hb variants. Here, we report the first pediatric case of hemoglobin I-High Wycombe [β59(E3) Lys → Glu] variant found in an infant of Mexican-American descent. The patient is thriving and has no clinical complication due to this hemoglobinopathy. In this case, globin chain analysis and peptide mapping by reversed phase high-performance liquid chromatography revealed the presence of hemoglobin I-High Wycombe which can easily be reported incorrectly as beta thalassemia trait.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120098"},"PeriodicalIF":3.2,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrochemical biosensors for depression: Diagnosis and therapeutic monitoring.","authors":"Amir Asadi, Felora Ferdosi, Sanam Anoosheh, Mahya Kaveh, Ehsan Dadgostar, Sajad Ehtiati, Ahmad Movahedpour, Hamed Khanifar, Malihe Mehdinejad Haghighi, Seyyed Hossein Khatami","doi":"10.1016/j.cca.2024.120091","DOIUrl":"10.1016/j.cca.2024.120091","url":null,"abstract":"<p><p>Electrochemical biosensors have revolutionized the detection of biomarkers related to depression and the quantification of antidepressant drugs. These biosensors leverage nanomaterials and advanced assay designs to achieve high sensitivity and selectivity for clinically relevant analytes. Key neurotransmitters implicated in depression, such as serotonin, dopamine, and glutamate, can be accurately measured via biosensors, providing insights into the effects of antidepressant treatments on neurotransmission. Biosensors can also detect biomarkers of inflammation, oxidative stress, and neuronal health that are altered in depression. Real-time biosensing techniques such as fast-scan cyclic voltammetry enable monitoring of dynamic neurotransmitter changes during depressive episodes and pharmacological interventions. Advancements incorporating graphene, gold nanoparticles, and other nanomaterials have enhanced biosensor performance, enabling the detection of low biomarker concentrations. Closed-loop biosensing systems hold promise for precision medicine by automating antidepressant dosage adjustments on the basis of neurotransmitter levels. A wide range of depression biomarkers, including apolipoprotein A4, heat shock protein 70, brain-derived neurotrophic factor, microRNAs, proteins, and combinatorial biomarker panels, have been detected via sophisticated biosensor platforms. Emerging biosensors show selectivity for antidepressant drugs such as serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and selective serotonin reuptake inhibitors in biological samples. This review emphasizes the transformative potential of electrochemical biosensors in combating depression. By facilitating earlier and more accurate diagnoses, these biosensors can revolutionize patient care and enhance treatment outcomes.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120091"},"PeriodicalIF":3.2,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in lateral flow assays for MicroRNA detection.","authors":"Nasim Barzegar Nafari, Majid Zamani, Bashir Mosayyebi","doi":"10.1016/j.cca.2024.120096","DOIUrl":"10.1016/j.cca.2024.120096","url":null,"abstract":"<p><p>Lateral flow assays (LFAs) have emerged as pivotal tools for the rapid and reliable detection of microRNAs (miRNAs). It is believed that these biomarkers are crucial for the diagnosis and prognosis of various diseases, particularly cancer. Traditional miRNA detection techniques, such as quantitative PCR, are highly sensitive but have limited efficacy due to their complexity, high cost, and technical requirements. LFAs are valuable due to their simplicity, affordability, and portability, making them ideal for point-of-care testing in low-resource environments. However, challenges remain in developing highly sensitive and accurate LFA devices for miRNA detection. This review explores recent advancements in LFAs to improve miRNA detection sensitivity and specificity. Key innovations include signal amplification using isothermal methods, the application of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas systems for direct targeting of miRNAs, and the incorporation of nanomaterials, such as gold nanoparticles and nanorods, to enhance signal intensity. Using artificial intelligence (AI) algorithms enables precise, automated, and rapid quantification of miRNAs. Moreover, this review examines the ability of LFA-based devices to detect multiple miRNAs simultaneously. One of the most significant advancements is the detection of miR-21 levels as low as 20 pM and let-7a levels as low as 40 pM within ten minutes. This highlights the potential of these devices for clinical diagnostics.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120096"},"PeriodicalIF":3.2,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosensors for the detection of celiac disease.","authors":"Asma Vafadar, Parisa Vosough, Shayan Khalili Alashti, Saeed Taghizadeh, Amir Savardashtaki","doi":"10.1016/j.cca.2024.120092","DOIUrl":"10.1016/j.cca.2024.120092","url":null,"abstract":"<p><p>Celiac disease (CeD) is an autoimmune disorder triggered by sensitivity to gluten, a protein complex found in wheat, barley, and rye. Gliadins, a component of gluten, are proteins that trigger an immune response in individuals with CeD, primarily affecting the small intestine's inner lining. Despite a 1-1.5% prevalence, only 24% of cases are diagnosed due to non-specific symptoms. Screening is advised for high-risk groups, including first-degree relatives and type 1 diabetes patients. The accurate diagnosis of this condition and the assessment of the patient's response to the current treatment - a lifelong gluten-free diet - necessitate using dependable, swift, sensitive, specific, uncomplicated, and affordable analytical methods. Detecting CeD biomarkers in whole blood, serum, or plasma provides a non-invasive approach that serves as an ideal initial diagnostic step. Biosensors offer a novel and alternative way for CeD detection, began emerging in 2007, and hold promise for clinical and point-of-care applications. This review explores the use of biomarker-based diagnostic approaches for CeD, with a focus on biosensors. It delves into the progress of biosensors for CeD diagnosis, identifying trends and challenges in this evolving field. Key biomarkers are highlighted, offering insights into the evolving landscape of biosensors in CeD detection.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120092"},"PeriodicalIF":3.2,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticle biosensors for cardiovascular disease detection.","authors":"Mohamed J Saadh, Faris Anad Muhammad, Rafid Jihad Albadr, Ashok Kumar Bishoyi, Suhas Ballal, Lakshay Bareja, K Satyam Naidu, Jasur Rizaev, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Ali M Ali Al-Nuaimi","doi":"10.1016/j.cca.2024.120094","DOIUrl":"https://doi.org/10.1016/j.cca.2024.120094","url":null,"abstract":"<p><p>Early detection and management of cardiovascular diseases (CVDs) are crucial for patient survival and long-term health. CVD biomarkers such as cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), Galectin-3 (Gal-3), etc are released into the circulation following heart muscle injury, ie, acute myocardial infarction (AMI). Biosensor technology including the use of nanoparticles can be designed to target specific biomarkers associated with CVD, enabling early detection and more rapid intervention to decrease morbidity and mortality. To date, with the combination of developed nanoparticles, several optical and electrochemical-based biosensors have successfully been used detection of CVD biomarkers. Nanomaterials, when introduced as the modifiers of sensor surfaces like electrodes and gold chips, can result in the more comprehensive and more effective immobilization of capture molecules, ie, antibodies, aptamers and other ligands, due to their large surface area. In recent years, inorganic nanoparticles have regularly been used in the production of biosensors mostly due to their excellent response intensification, adaptable functionalization chemistry, shape control, good biocompatibility, and great stability. In this review, we discuss the application of different kinds of nanoparticles for the sensitive and specific detection of CVD biomarkers.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120094"},"PeriodicalIF":3.2,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in laboratory diagnosis of Sjogren's disease in children.","authors":"Yuemeng Li, Wenxiu He, Yu Zhou, Haotian Chen, Pengyue You, Danni Mu, Yichen Ma, Yumeng Gao, Kaiduo Xu, Haitao Dong, Xinqi Cheng","doi":"10.1016/j.cca.2024.120095","DOIUrl":"https://doi.org/10.1016/j.cca.2024.120095","url":null,"abstract":"<p><p>Sjogren's disease (SjD) in children is a rare chronic autoimmune disease not fully recognized due to clinical manifestations different from adults. As such, new objective indicators are needed to supplement existing markers and assist in diagnosis. This review summarizes pathogenesis of SjD in children, current diagnostic criteria and research progress in laboratory diagnosis including serologic testing, saliva and tear analysis, histopathological examination as well as emerging markers of interest.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120095"},"PeriodicalIF":3.2,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}